

**DEPARTMENT OF HEALTH CARE FINANCE
NOTICE OF PUBLIC MEETING**

Department of Health Care Finance Pharmacy and Therapeutics Committee

The Department of Health Care Finance (DHCF) Pharmacy and Therapeutics Committee (Committee), pursuant to the requirements of Mayor’s Order 2007-46, dated January 23rd, 2007 hereby announces a public meeting of the Committee to obtain input on the review and maintenance of a Preferred Drug List (PDL) for the District of Columbia. The meeting will be held **Thursday, December 3rd, 2020 at 2:30 PM** during a webinar.

Please note in order to attend the meeting, **you will have to register at the website:** https://magellanhealth.zoom.us/webinar/register/WN_XV7PVkorR8G0ZIC18zGpiw. Once registered you will receive an email with instructions on how to attend the webinar.

The Committee will receive public comments from interested individuals on issues relating to the topics or class reviews to be discussed at this meeting. The clinical drug class review for this meeting will include:

- | | |
|--|--|
| Angiotensin Modulator Combinations | Hemophilia Agents (<i>Tentative</i>) |
| Angiotensin Modulators | Hepatitis B Agents |
| Antianginal Agents (Ranexa) | Hepatitis C Agents |
| Antibiotics, Topical | HIV and AIDS Treatments |
| Anticoagulants | Immunomodulators, Atopic Dermatitis |
| Antihypertensives, Sympatholytics | Immunomodulators, Topical |
| Antipsoriatics, Oral | Lipotropics, Others |
| Antipsoriatics, Topical | Lipotropics, Statins |
| Antiviral Agents, Oral (HSV & Influenza) | Methotrexate |
| Antiviral Agents, Topical | Platelet Aggregation Inhibitors |
| Beta-Blockers | Rosacea Agents, Topical |
| Calcium Channel Blockers | Sickle Cell Anemia Agents (<i>Tentative</i>) |

Any person or organizations who wish to make a presentation to the DHCF P&T Committee should furnish his or her name, address, telephone number, and name of organization represented by calling (202) 442-9076 **no later than 4:45 PM Wednesday, November 25th, 2020**. The person or organization may also submit the aforementioned information via e-mail to Charlene Fairfax (charlene.fairfax@dc.gov).

An individual wishing to make an oral presentation to the Committee will be limited to three (3) minutes.

A person wishing to provide written information should supply a copy of the written information to the Committee **no later than 4:45 PM Wednesday, November 25th, 2020**. **Handouts are limited to no more than two standard 8-1/2 by 11 inch pages of “bulleted” points (or one page front and back)**. The ready-to-disseminate, written information should be emailed to charlene.fairfax@dc.gov **to arrive no later than Wednesday, November 25th, 2020**.